Developer docs
API playgroundTry for free, no card

Search company profiles

AM Pharma

Full company profile

uuid0002yd9

Namestring
AM Pharma
Legal namestring
AM-Pharma Holding B.V./AM-Pharma B.V.
Websiteurl
am-pharma.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

AM-Pharma is a clinical-stage biopharmaceutical company headquartered in Utrecht, the Netherlands, founded in 2001/2002, that develops a single proprietary therapeutic candidate, ilofotase alfa (recombinant human alkaline phosphatase, engineered from two naturally occurring human isoforms of the alkaline phosphatase enzyme). The compound acts via two mechanisms: enzyme replacement that reduces elevated pyridoxal-5′-phosphate (PLP) and inorganic pyrophosphate (PPi) substrates central to hypophosphatasia (HPP), and dephosphorylation of lipopolysaccharides (LPS) and extracellular ATP that inactivates pro-inflammatory ATP and produces adenosine acting on the immunosuppressive A2a receptor pathway. Following a positive Phase II STOP-AKI study (301 patients, published in JAMA, demonstrating >40% relative mortality reduction), the pivotal Phase III REVIVAL trial in sepsis-associated AKI was stopped in October 2022 for futility. AM-Pharma then pivoted development to adult HPP, where the Phase 1b study showed dose-dependent normalization of alkaline phosphatase activity and pharmacologic effects on all HPP-specific biomarkers (PPi, PLP, PEA) with no safety concerns, and has additionally initiated a Phase 2 trial in cardiac surgery-associated renal damage (enrollment completed October 2025).

The asset is protected by FDA and EMA orphan drug designation for hypophosphatasia and previously held FDA Fast Track for SA-AKI; ~1,000 patients have been exposed to ilofotase alfa across clinical studies. AM-Pharma has raised more than EUR 240 million in equity and debt from a European-led syndicate that includes LSP/EQT Life Sciences, Andera Partners, Forbion, Ysios Capital, Kurma Partners, Gilde Healthcare, Idinvest Partners, Pureos Bioventures, and corporate venture investors Pfizer, Takeda, and Nestlé Health Sciences, plus an innovation credit from the Netherlands Enterprise Agency (RVO).

AM-Pharma's revenue model is currently milestone-driven: the September 2021 exclusive license with Kyowa Kirin covers Japan and provides a EUR 20 million upfront, up to EUR 245 million in development, regulatory and sales milestones, tiered double-digit royalties, and drug supply fees. Outside Japan, AM-Pharma is building toward direct commercialization to hospitals and ICUs for acute indications (via IV) and to adult HPP patients via subcutaneous injection; a U.S. affiliate (AM-Pharma Inc.) was established in September 2021 and commercial-oriented hires (CFO, VP Commercial Strategy, VP Value & Market Access, CBO) have been added. The customer base for the eventual product is fragmented across hospital systems and rare-disease patient populations (HPP), with no commercial product currently generating revenue.

Short descriptiontext

AM-Pharma is a clinical-stage biopharmaceutical company developing ilofotase alfa, a proprietary recombinant human alkaline phosphatase, for adult hypophosphatasia and cardiac surgery-associated renal damage. Headquartered in Utrecht, Netherlands; partnered with Kyowa Kirin for Japan.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersUtrecht, Netherlands
HQ citystring
Utrecht
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biopharmaceutical therapeutics, enzyme replacement therapy, recombinant alkaline phosphatase, acute kidney injury treatment, rare disease therapeutics
Industry2 codes
PRIMARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Biopharmaceutical Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

AM-Pharma receives upfront payments, development and regulatory milestones, and sales milestones from licensing partners. Deal with Kyowa Kirin includes EUR 20 million upfront, EUR 30 million pre-submission milestones, up to EUR 195 million upon submission, NHI price listing and sales milestones, plus tiered double-digit royalties on sales and drug supply fees.

am-pharma.com
2Pharmaceutical Product Sales
TypeOne Time License
Description

Revenue from direct commercialization of ilofotase alfa upon regulatory approval for treatment of sepsis-associated acute kidney injury (SA-AKI) and hypophosphatasia (HPP).

am-pharma.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

AM-Pharma is a clinical-stage biopharmaceutical company developing ilofotase alfa, a proprietary recombinant human alkaline phosphatase (rhAP) enzyme replacement therapy. The compound is being advanced for adult hypophosphatasia (HPP) as a Phase 2-ready program, with prior development in sepsis-associated acute kidney injury (SA-AKI) and ongoing work in cardiac surgery-associated renal damage. The drug targets severe inflammatory and infectious diseases where there are no approved pharmacological treatments.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Phase II STOP-AKI: >40% relative reduction in mortality compared to placebo in sepsis-associated AKI patients
+4 more records
Product overview1 text field

AM Pharma is a clinical-stage biopharmaceutical company developing a single proprietary therapeutic compound, ilofotase alfa (recombinant human alkaline phosphatase). The drug is being developed for multiple indications: sepsis-associated acute kidney injury (SA-AKI) as the lead indication in Phase III (REVIVAL trial), hypophosphatasia (HPP) as Phase 2-ready, and cardiac surgery-associated renal damage in Phase 2. Ilofotase alfa acts as an enzyme replacement therapy addressing elevated levels of pyridoxal-5′-phosphate (PLP) and inorganic pyrophosphates (PPi), with a dual mechanism of action via dephosphorylation of DAMPs and PAMPs.

Product and service1 record
1Ilofotase alfa (recombinant human Alkaline Phosphatase)
CategoryBiopharmaceutical Therapeutic
Description

Proprietary recombinant human alkaline phosphatase (rhAP) therapeutic candidate constructed from two human isoforms. Being developed as enzyme replacement therapy for adult hypophosphatasia (HPP), with prior Phase III development for sepsis-associated acute kidney injury (SA-AKI) and Phase 2 development for cardiac surgery-associated renal damage. Administered via subcutaneous injection for HPP and IV for acute conditions. Demonstrated to be well-tolerated, stable, and highly active in multiple clinical trials.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-09-08
Description

Exclusive license agreement for development and commercialization of ilofotase alfa in Japan. AM-Pharma receives EUR 20 million upfront, EUR 30 million pre-submission milestones, up to EUR 195 million upon submission, NHI price listing and sales milestones, tiered double-digit royalties on sales, and drug supply fee. Kyowa Kirin responsible for regulatory approval and commercialization in Japan.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Global rare disease biotech with multiple approved enzyme replacement and biologics therapies for rare genetic conditions including HPP-adjacent metabolic disorders. Comparable in scale, clinical stage asset portfolio, and orphan drug strategy.

TypeDirect peer
Description

Markets Strensiq (asfotase alfa), the only approved enzyme replacement therapy for hypophosphatasia and the direct competitive incumbent to AM-Pharma's ilofotase alfa. Both companies develop biologics for rare genetic metabolic disorders and target the same HPP prescriber base.

TypeDirect peer
Description

Rare disease biotech focused on enzyme replacement therapies and gene therapies for devastating genetic conditions, with approved products and pipeline assets addressing similar patient populations. Closely comparable development model and therapeutic categories.

TypeDirect peer
Description

Clinical-stage and commercial rare disease biotech focused on novel therapies for serious rare and ultra-rare genetic diseases, with multiple enzyme and protein replacement therapies in development or on market. Directly comparable business model, target indications (rare metabolic diseases), and development stage to AM-Pharma.

TypeBroad incumbent
Description

Global pharmaceutical incumbent that held an exclusive option to acquire AM-Pharma (paid $87.5M upfront in 2015, did not exercise). Operates broadly in rare diseases and nephrology-relevant therapeutic areas; relevant as both a current investor and potential future strategic acquirer.

TypeDirect peer
Description

Clinical-stage gene therapy company focused on rare genetic metabolic and immune disorders, including programs that could compete or combine with enzyme replacement approaches like ilofotase alfa. Similar development stage and rare disease specialization.

TypeDirect peer
Description

Clinical-stage biotech developing targeted therapies for genetic diseases and cancers, including rare disease programs in similar developmental stages to AM-Pharma's pipeline. Comparable business model of advancing multiple indications from a focused genetic disease platform.

TypeBroad incumbent
Description

Global pharma with a substantial rare disease franchise (post-Shire acquisition) and existing investor in AM-Pharma. Operates broadly across nephrology, metabolic, and rare disease indications overlapping with AM-Pharma's therapeutic focus.

TypeEmerging player
Description

Privately-held specialty pharma with a growing rare disease franchise (gained through the $1.85B acquisition of Amryt Pharma) focused on metabolic and enzyme deficiency disorders. Potential strategic acquirer of regional rights or partner for ilofotase alfa commercialization.

TypeDirect peer
Description

Specialty biopharma focused on rare diseases, with a portfolio including enzyme replacement therapies and biologics for rare inflammatory and genetic conditions. Highly comparable target market, distribution model through specialty channels, and orphan drug focus.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

AM Pharma

Biopharmaceutical Therapeuticsam-pharma.com

AM-Pharma is a clinical-stage biopharmaceutical company developing ilofotase alfa, a proprietary recombinant human alkaline phosphatase, for adult hypophosphatasia and cardiac surgery-associated renal damage. Headquartered in Utrecht, Netherlands; partnered with Kyowa Kirin for Japan.

What AM Pharma does

AM-Pharma is a clinical-stage biopharmaceutical company headquartered in Utrecht, the Netherlands, founded in 2001/2002, that develops a single proprietary therapeutic candidate, ilofotase alfa (recombinant human alkaline phosphatase, engineered from two naturally occurring human isoforms of the alkaline phosphatase enzyme). The compound acts via two mechanisms: enzyme replacement that reduces elevated pyridoxal-5′-phosphate (PLP) and inorganic pyrophosphate (PPi) substrates central to hypophosphatasia (HPP), and dephosphorylation of lipopolysaccharides (LPS) and extracellular ATP that inactivates pro-inflammatory ATP and produces adenosine acting on the immunosuppressive A2a receptor pathway. Following a positive Phase II STOP-AKI study (301 patients, published in JAMA, demonstrating >40% relative mortality reduction), the pivotal Phase III REVIVAL trial in sepsis-associated AKI was stopped in October 2022 for futility. AM-Pharma then pivoted development to adult HPP, where the Phase 1b study showed dose-dependent normalization of alkaline phosphatase activity and pharmacologic effects on all HPP-specific biomarkers (PPi, PLP, PEA) with no safety concerns, and has additionally initiated a Phase 2 trial in cardiac surgery-associated renal damage (enrollment completed October 2025).

The asset is protected by FDA and EMA orphan drug designation for hypophosphatasia and previously held FDA Fast Track for SA-AKI; ~1,000 patients have been exposed to ilofotase alfa across clinical studies. AM-Pharma has raised more than EUR 240 million in equity and debt from a European-led syndicate that includes LSP/EQT Life Sciences, Andera Partners, Forbion, Ysios Capital, Kurma Partners, Gilde Healthcare, Idinvest Partners, Pureos Bioventures, and corporate venture investors Pfizer, Takeda, and Nestlé Health Sciences, plus an innovation credit from the Netherlands Enterprise Agency (RVO).

AM-Pharma's revenue model is currently milestone-driven: the September 2021 exclusive license with Kyowa Kirin covers Japan and provides a EUR 20 million upfront, up to EUR 245 million in development, regulatory and sales milestones, tiered double-digit royalties, and drug supply fees. Outside Japan, AM-Pharma is building toward direct commercialization to hospitals and ICUs for acute indications (via IV) and to adult HPP patients via subcutaneous injection; a U.S. affiliate (AM-Pharma Inc.) was established in September 2021 and commercial-oriented hires (CFO, VP Commercial Strategy, VP Value & Market Access, CBO) have been added. The customer base for the eventual product is fragmented across hospital systems and rare-disease patient populations (HPP), with no commercial product currently generating revenue.

AM Pharma firmographics

Firmographics
Name
AM Pharma
Legal name
AM-Pharma Holding B.V./AM-Pharma B.V.
Website
https://am-pharma.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
11–50 employees
Short description
AM-Pharma is a clinical-stage biopharmaceutical company developing ilofotase alfa, a proprietary recombinant human alkaline phosphatase, for adult hypophosphatasia and cardiac surgery-associated renal damage. Headquartered in Utrecht, Netherlands; partnered with Kyowa Kirin for Japan.
Ownership category
akta.pro rank

AM Pharma industry classification

Industry
Product category
Biopharmaceutical Therapeutics
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAH
Nephrology & Urology Specialty Pharmaceuticals
SECONDARYHLAIACAB
Immunology & Autoimmune Specialty Pharmaceuticals

Keywords

  • Biopharmaceutical therapeutics
  • Enzyme replacement therapy
  • Recombinant alkaline phosphatase
  • Acute kidney injury treatment
  • Rare disease therapeutics

Where AM Pharma is headquartered

Location

Headquarters

HQ city
Utrecht
HQ country
Netherlands
HQ region
Europe

Offices2 records

Markets served

AM Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Licensing and Milestone Payments: AM-Pharma receives upfront payments, development and regulatory milestones, and sales milestones from licensing partners. Deal with Kyowa Kirin includes EUR 20 million upfront, EUR 30 million pre-submission milestones, up to EUR 195 million upon submission, NHI price listing and sales milestones, plus tiered double-digit royalties on sales and drug supply fees.
  2. Pharmaceutical Product Sales: Revenue from direct commercialization of ilofotase alfa upon regulatory approval for treatment of sepsis-associated acute kidney injury (SA-AKI) and hypophosphatasia (HPP).

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

AM Pharma product offering

Product offering

Core offering

AM-Pharma is a clinical-stage biopharmaceutical company developing ilofotase alfa, a proprietary recombinant human alkaline phosphatase (rhAP) enzyme replacement therapy. The compound is being advanced for adult hypophosphatasia (HPP) as a Phase 2-ready program, with prior development in sepsis-associated acute kidney injury (SA-AKI) and ongoing work in cardiac surgery-associated renal damage. The drug targets severe inflammatory and infectious diseases where there are no approved pharmacological treatments.

Product overview

AM Pharma is a clinical-stage biopharmaceutical company developing a single proprietary therapeutic compound, ilofotase alfa (recombinant human alkaline phosphatase). The drug is being developed for multiple indications: sepsis-associated acute kidney injury (SA-AKI) as the lead indication in Phase III (REVIVAL trial), hypophosphatasia (HPP) as Phase 2-ready, and cardiac surgery-associated renal damage in Phase 2. Ilofotase alfa acts as an enzyme replacement therapy addressing elevated levels of pyridoxal-5′-phosphate (PLP) and inorganic pyrophosphates (PPi), with a dual mechanism of action via dephosphorylation of DAMPs and PAMPs.

Differentiator

Problem solved

Functional benefit

Products and services

  • Ilofotase alfa (recombinant human Alkaline Phosphatase) Proprietary recombinant human alkaline phosphatase (rhAP) therapeutic candidate constructed from two human isoforms. Being developed as enzyme replacement therapy for adult hypophosphatasia (HPP), with prior Phase III development for sepsis-associated acute kidney injury (SA-AKI) and Phase 2 development for cardiac surgery-associated renal damage. Administered via subcutaneous injection for HPP and IV for acute conditions. Demonstrated to be well-tolerated, stable, and highly active in multiple clinical trials.

Quantifiable outcome

  • Phase II STOP-AKI: >40% relative reduction in mortality compared to placebo in sepsis-associated AKI patients
  • +4 more outcomes

Companies that use AM Pharma

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles3 records

AM Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

AM Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Kyowa KirincoreOEM/ Whitelabel/ Licensing Partner · 8 September 2021Exclusive license agreement for development and commercialization of ilofotase alfa in Japan. AM-Pharma receives EUR 20 million upfront, EUR 30 million pre-submission milestones, up to EUR 195 million upon submission, NHI price listing and sales milestones, tiered double-digit royalties on sales, and drug supply fee. Kyowa Kirin responsible for regulatory approval and commercialization in Japan.

Scale indicators13 records

Recent moves7 records

Expansion highlights6 records

AM Pharma competitors and assessment

Company assessment

Direct peers

  • BioMarin Pharmaceutical: Global rare disease biotech with multiple approved enzyme replacement and biologics therapies for rare genetic conditions including HPP-adjacent metabolic disorders. Comparable in scale, clinical stage asset portfolio, and orphan drug strategy.
  • Alexion (AstraZeneca Rare Disease): Markets Strensiq (asfotase alfa), the only approved enzyme replacement therapy for hypophosphatasia and the direct competitive incumbent to AM-Pharma's ilofotase alfa. Both companies develop biologics for rare genetic metabolic disorders and target the same HPP prescriber base.
  • Amicus Therapeutics: Rare disease biotech focused on enzyme replacement therapies and gene therapies for devastating genetic conditions, with approved products and pipeline assets addressing similar patient populations. Closely comparable development model and therapeutic categories.
  • Ultragenyx Pharmaceutical: Clinical-stage and commercial rare disease biotech focused on novel therapies for serious rare and ultra-rare genetic diseases, with multiple enzyme and protein replacement therapies in development or on market. Directly comparable business model, target indications (rare metabolic diseases), and development stage to AM-Pharma.
  • Orchard Therapeutics: Clinical-stage gene therapy company focused on rare genetic metabolic and immune disorders, including programs that could compete or combine with enzyme replacement approaches like ilofotase alfa. Similar development stage and rare disease specialization.
  • BridgeBio Pharma: Clinical-stage biotech developing targeted therapies for genetic diseases and cancers, including rare disease programs in similar developmental stages to AM-Pharma's pipeline. Comparable business model of advancing multiple indications from a focused genetic disease platform.
  • Swedish Orphan Biovitrum (Sobi): Specialty biopharma focused on rare diseases, with a portfolio including enzyme replacement therapies and biologics for rare inflammatory and genetic conditions. Highly comparable target market, distribution model through specialty channels, and orphan drug focus.

Broad incumbents

  • Pfizer: Global pharmaceutical incumbent that held an exclusive option to acquire AM-Pharma (paid $87.5M upfront in 2015, did not exercise). Operates broadly in rare diseases and nephrology-relevant therapeutic areas; relevant as both a current investor and potential future strategic acquirer.
  • Takeda Pharmaceutical: Global pharma with a substantial rare disease franchise (post-Shire acquisition) and existing investor in AM-Pharma. Operates broadly across nephrology, metabolic, and rare disease indications overlapping with AM-Pharma's therapeutic focus.

Emerging players

  • Chiesi Farmaceutici: Privately-held specialty pharma with a growing rare disease franchise (gained through the $1.85B acquisition of Amryt Pharma) focused on metabolic and enzyme deficiency disorders. Potential strategic acquirer of regional rights or partner for ilofotase alfa commercialization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

AM Pharma social profiles

Digital presence

AM Pharma compliance and trust

Trust signal

Compliance3 records

AM Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

AM Pharma leadership team

Management profile

Number of profiles

Profiles20 records

AM Pharma subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

AM Pharma funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

AM Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AM Pharma

What does AM Pharma do?

AM-Pharma is a clinical-stage biopharmaceutical company developing ilofotase alfa, a proprietary recombinant human alkaline phosphatase (rhAP) enzyme replacement therapy. The compound is being advanced for adult hypophosphatasia (HPP) as a Phase 2-ready program, with prior development in sepsis-associated acute kidney injury (SA-AKI) and ongoing work in cardiac surgery-associated renal damage. The drug targets severe inflammatory and infectious diseases where there are no approved pharmacological treatments.

Is AM Pharma a public or private company?

AM Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was AM Pharma founded?

AM Pharma was founded in 2002. It employs 11 to 50 people.

Where is AM Pharma based?

AM Pharma is headquartered in Utrecht, Netherlands, in the Europe region.

How does AM Pharma make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are pharmaceutical Product Sales.

Who are AM Pharma's main competitors?

Direct peers on record are BioMarin Pharmaceutical, Alexion (AstraZeneca Rare Disease), Amicus Therapeutics, Ultragenyx Pharmaceutical, Orchard Therapeutics, BridgeBio Pharma and Swedish Orphan Biovitrum (Sobi). Broad incumbents are Pfizer and Takeda Pharmaceutical. Chiesi Farmaceutici is listed as an emerging player.

Does AM Pharma have an API?

No public API is recorded for AM Pharma.

What industry is AM Pharma in?

AM Pharma's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals, with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
WebcapitalriesgoAmbrose Healthcare adquiere AM-Pharma, participada por Ysios, por hasta €161M, ampliando su cartera de productos para enfermedades raras y obteniendo una base europeaAmbrose Healthcare acquired 100% of AM-Pharma for up to €161M, including milestone payments and royalties. The deal adds ilofotasa alfa for hypophosphatasia to its pipeline and gives Ambrose its first European base in Utrecht. The company will continue evaluating future acquisitions.EIN PresswireAmbrose expands rare disease pipeline with €161M AM-Pharma acquisition - European Biotechnology MagazineAmbrose Healthcare acquired AM-Pharma for up to €161 million, adding ilofotase alfa to its rare disease pipeline. The enzyme replacement therapy, previously stalled in kidney disease, is now ready for Phase 2 in hypophosphatasia, with orphan drug designations in the U.S. and Europe. Ambrose aims to develop it faster and cheaper.Business & FinancialAmbrose Healthcare Acquires AM-Pharma For Up To €161 Million, Expanding Its Rare Disease Pipeline And Gaining A European BaseAmbrose Healthcare acquired AM-Pharma for up to €161 million, adding ilofotase alfa to its rare disease pipeline. The enzyme replacement therapy has orphan drug status from the FDA and EMA and a safety database of nearly 700 patients. The deal gives Ambrose a European platform and a third asset.Pharmaceutical TechnologyAmbrose Healthcare fortifies rare disease pipeline on AM-Pharma takeover - Pharmaceutical TechnologyAmbrose Healthcare acquired 100% of AM-Pharma, adding ilofotase alfa, a Phase II-ready enzyme replacement therapy for hypophosphatasia. The deal includes up to €161m in upfront and milestone payments, and expands Ambrose's European presence. The acquisition aims to challenge AstraZeneca's Strensiq, which is losing exclusivity in 2027.GlobeNewswireAmbrose Healthcare Acquires AM-Pharma for Up to €161 Million, Expanding its Rare Disease Pipeline and Gaining a European BaseAmbrose Healthcare acquired 100% of AM-Pharma for up to €161 million, including upfront and milestone payments. The deal adds ilofotase alfa for hypophosphatasia to Ambrose's pipeline and gives it a European base in Utrecht. No further financial terms were disclosed.FierceBiotechAmbrose Healthcare inks $181M deal for former Pfizer target AM-PharmaAmbrose Healthcare acquired AM-Pharma for up to $181 million, including an upfront payment and milestones tied to commercializing ilofotase alfa in hypophosphatasia. The deal follows AM-Pharma's failed phase 3 sepsis trial and pivot to HPP, where Ambrose plans to apply its rare disease expertise.BioSpaceAM-Pharma to Participate in Upcoming Jefferies Healthcare ConferenceAM-Pharma Holding BV announced that CFO Lars Boesgaard will present at the Jefferies Healthcare Conference in New York on June 8, 2022. The company focuses on sepsis-associated acute kidney injury, with its compound ilofotase alfa in a global Phase III trial.BioSpaceAM-Pharma Appoints Lars Boesgaard as Chief Financial Officer and Establishes U.S. Affiliate AM-Pharma Inc.AM-Pharma appointed Lars Boesgaard as CFO, effective immediately, and established U.S. affiliate AM-Pharma Inc. Boesgaard, with 25 years of experience, will be the first U.S.-based executive, supporting potential U.S. commercialization of ilofotase alfa in Phase III clinical development.FierceBiotechKyowa Kirin to pay AM-Pharma up to $289M in licensing deal for Pfizer-rejected sepsis assetKyowa Kirin will pay up to $289 million for exclusive licensing of AM-Pharma's phase 3 sepsis drug ilofotase alfa. The deal includes €20 million upfront, €30 million milestones, and €195 million upon approval filing. AM-Pharma leads the pivotal trial, with completion scheduled for August 15, 2023.UnquoteCowen Healthcare in €47m extension round for AM-PharmaAM-Pharma raised €47m, including €23m equity from Cowen Healthcare and €24m from the EIB. The funding supports a phase-III trial of its recAP for sepsis-associated acute kidney injury with 1,400 patients across 12 countries. The trial's completion will enable marketing authorisation applications.